Selection and Evaluation of Human Recombinant Antibodies against ErbB2 Antigen for Breast Cancer Immunotherapy

Abstract

Background: Breast cancer is the most common cause of cancer-related death in women worldwide. ErBb2/HER2 breast cancer accounts for 25% -30% of all cases of breast cancer. Approved anti-ErbB2 monoclonal antibodies, trastuzumab and pertuzumab, are currently used for the treatment of ErbB-positive breast cancer, although their clinical use is limited due to their immunogenicity. Human recombinant single-chain antibodies, which are produced by antibody engineering technologies, are new and effective antibodies in cancer immunotherapy.